Not exactly accurate. My reading indicates that the resubmission in August 1011 included "In addition to the data filed from the original NDA and additional analyses of some of those data, Alexza also included new data from the successfully completed human factors study, stability data from new production batches manufactured late last year, updated manufacturing and controls sections addressing findings from the Pre-Approval Inspection, and updated draft labeling and a comprehensive REMS proposal in the re-file." (Jason Napadono, Seeking Alpha 8/9/2011)
Speaking of other message topics - the NCR you brought up back in January has made a nice move. Hope you followed your own advice and bought some.
As I recall, he initiated his HUN position in the 3's, just after he closed out his ROH position in the ROH/DOW acquisition. He was also buying some DOW in case the deal didn't happen, so did well on both sides. Nice to see you drop in, Moose.
Jon Sr has sold some stock on a regular basis to fund his ongoing commitment to the Huntsman Cancer Institute. What's your point?
They've had another partner, Grupo Ferrer, since 2011.
"Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and will be Alexza's partner in the registration, distribution and promotion of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries."
Actual expiration is the 3rd Saturday of the month. However, since the exchanges are closed on weekends, the 3rd Friday is the last trading day. This month it's the 17th.
Just curious. How did the Teva deal impact the exit strategy you outlined back in January - executed as planned, or was the deal good enough to persuade you to revise it?
Overlooked the split. Makes more sense re price movement today. 44,000 warrants wouldn't have had any meaningful impact on share price today against a nearly 9 million volume.
Looks like 44,000 if this article is correct.
Alexza Pharmaceuticals, Inc. Prices USD22 Million Public Offering
Friday, 17 Feb 2012 07:59am EST
Alexza Pharmaceuticals, Inc. announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock. The common stock and warrants will be issued separately, but will be sold in combination in the offering, with a warrant to purchase one share of common stock for each share of common stock sold. The price to the public for each share and related warrant is USD0.50 , for an aggregate offering amount of approximately USD22 million .
Definitely shown as automatic program sales on the Form 4's. However, this is the second time in less than a year when those sale triggers just happened to occur coincident with the announcement of test results that resulted in a huge jump in the share price. Note the results announcement last year was subsequently withdrawn as being in error. If you're curious or weren't aware, google Vertex 10b5-1.
Smith commented on that in more detail in the Q&A portion of the presentation. See his response to a JMP Securities question. From the SA transcript. "then it also has a soft call feature. Sometimes people aren't aware of that, but it does have a soft call feature that if the debt trades just above $63 for 20 days out of 30, then we do have the opportunity, and we'll have the intent to convert it into equity."
Understand your point, and there's certainly nothing wrong with taking a profit. The concern is the extent of the sale - at least as I see it.
If I'm the CFO of a company, that means I'm aware of all the test information, financial issues if any, company strategies and any other future issues the company may face. So while I may logically want to take a profit on part of my position to minimize any future risks, a sale of almost all of it indicates two things, at least IMO. (1) I know the huge run up on the 661 results was only hype and fast money pushing the share price up so much, or (2) based on my knowledge of the company and any issues not made public, I don't have a lot of faith in the company future, at least as it pertains to holding the share price at anywhere close to the current value.
Per their website, a boutique equity research firm and full service broker-dealer catering to institutional investors. In business since 1964.